agilon health (AGL) Stock Forecast & Price Target

$2.05 +0.05 (+2.50%)

(As of 10:09 AM ET)

agilon health - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce

Based on 21 Analyst Ratings

Sell
3

Hold
16

Buy
2

Based on 21 Wall Street analysts who have issued ratings for agilon health in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 21 analysts, 3 have given a sell rating, 16 have given a hold rating, and 2 have given a buy rating for AGL.

Consensus Price Target

$4.28
108.94% Upside

According to the 21 analysts' twelve-month price targets for agilon health, the average price target is $4.28. The highest price target for AGL is $9.00, while the lowest price target for AGL is $1.75. The average price target represents a forecasted upside of 108.94% from the current price of $2.05.

Get the Latest News and Ratings for AGL and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for agilon health and its competitors.

AGL Analyst Ratings Over Time

Type	Current Forecast 12/19/23 to 12/18/24	1 Month Ago 11/19/23 to 11/18/24	3 Months Ago 9/20/23 to 9/19/24	1 Year Ago 12/19/22 to 12/19/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	2 Buy rating(s)	4 Buy rating(s)	7 Buy rating(s)
Hold	16 Hold rating(s)	15 Hold rating(s)	14 Hold rating(s)	2 Hold rating(s)
Sell	3 Sell rating(s)	3 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$4.28	$6.38	$8.57	$21.36
Forecasted Upside	108.94% Upside	305.29% Upside	121.93% Upside	63.02% Upside
Consensus Rating	Reduce	Reduce	Hold	Moderate Buy

Genesis leading the smart algo revolution? (Ad)

I’m revealing an exciting breakthrough that can help trade the markets unlike anything you’ve ever seen before… Because with my BRAND NEW smart algo you’ll always have a constant stream of alerts firing off in your back pocket to choose from. Here’s why: It does all the heavy lifting for you… automatically. Stock Ticker, Entry Price, Profit Target, Stop Loss, and even an Individual Chart!

You’ll want to see what I’ve put on this page right here

AGL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

AGL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

agilon health Stock vs. The Competition

Type	agilon health	Medical Companies	S&P 500
Consensus Rating Score	1.95	2.81	2.51
Consensus Rating	Reduce	Moderate Buy	Moderate Buy
Predicted Upside	113.63% Upside	28,526.48% Upside	12.04% Upside
News Sentiment Rating	Positive News See Recent AGL News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/16/2024	Macquarie 1 of 5 stars	T. Qiu Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$3.00	+33.93%
12/11/2024	Sanford C. Bernstein 3 of 5 stars	L. Wilkes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Market Perform	$2.50	+19.05%
11/19/2024	Royal Bank of Canada 4 of 5 stars		Reiterated Rating	Outperform ➝ Outperform	$3.00 ➝ $3.00	+86.92%
11/13/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Grosslight Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Sell ➝ Sell	$2.50 ➝ $1.75	-5.41%
11/12/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$7.00 ➝ $2.00	+6.95%
11/11/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$6.00 ➝ $2.00	-1.96%
Why I'm telling friends to avoid gold stocks (Ad) Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles." And if you’d like to get your hands on this, here you go, the complete breakdown.
11/11/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Underweight ➝ Underweight	$5.00 ➝ $2.00	+7.53%
11/11/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Davides Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
11/8/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Daniels Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
10/8/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	In-Line ➝ In-Line	$7.00 ➝ $4.00	+25.79%
10/2/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Underperform	$3.00	-14.53%
8/9/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$5.00 ➝ $4.00	-27.67%
8/8/2024	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00	+57.89%
5/30/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Ha Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
5/30/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$6.00	+4.08%
5/24/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$6.40 ➝ $6.50	+15.15%
2/26/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Hold	$25.00 ➝ $6.50	+3.67%
1/8/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	W. Mayo Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
1/8/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
1/8/2024	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Peer Perform
1/5/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Neutral	$17.00 ➝ $9.00	+12.36%
12/11/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$14.00	+21.21%
11/13/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$23.00 ➝ $16.00	+47.47%
3/6/2023	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$21.00 ➝ $30.00	+18.95%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 10:29 AM ET.

AGL Forecast - Frequently Asked Questions

: According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for agilon health is $4.28, with a high forecast of $9.00 and a low forecast of $1.75.
: 21 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for agilon health in the last year. There are currently 3 sell ratings, 16 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" AGL shares.
: According to analysts, agilon health's stock has a predicted upside of 108.94% based on their 12-month stock forecasts.
: Over the previous 90 days, agilon health's stock had 3 downgrades by analysts.
: agilon health has been rated by research analysts at Bank of America, Barclays, Citigroup, Evercore ISI, JMP Securities, Macquarie, Royal Bank of Canada, Sanford C. Bernstein, Stifel Nicolaus, TD Cowen, and William Blair in the past 90 days.
: Analysts like agilon health less than other "medical" companies. The consensus rating for agilon health is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AGL compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Vacuum up cash with these special trades? (Ad)

Have you ever heard about a “volatility vacuum?” Most people haven’t. It all revolves around this formula right here. Now, the most important thing is that this equation — when applied to certain tickers at a certain time each month —- can trigger these “volatility vacuums.” And when that happens, anyone has the shot at sucking out payouts of $290, $350, even $1,350 in as little as 24 hours. (With just a $1k starting stake!) Granted, there were smaller wins and those that did not work out but best of all, we can know exactly when these opportunities will hit. I’ve used this info to create a Cash Calendar that lays out the precise dates of these payouts.

And I’m sending it for FREE to anyone who joins me during my FREE training right here.

This page (NYSE:AGL) was last updated on 12/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

agilon health (AGL) Stock Forecast & Price Target